Please login to the form below

Not currently logged in
Email:
Password:

pulmonary embolism

This page shows the latest pulmonary embolism news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

There was a fatality from a stroke in the trial in a patient, plus one case of a pulmonary embolism, although AbbVie said these occurred in at-risk patients.

Latest news

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    Janssen's parent company Johnson &Johnson (J&J) said in a statement that up to 10% of people who have suffered a VTE (usually a deep vein thrombosis or pulmonary embolism)

  • NICE recommends Daiichi Sankyo's Lixiana for DVT and PE NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

    NICE has backed Daiichi Sankyo's Lixiana (edoxaban) in final guidance as a treatment for adults with deep vein thrombosis and pulmonary embolism. ... NICE concluded that Lixiana was a cost-effective use of NHS resources for deep vein thrombosis (DVT) and

  • Daiichi’s new anticoagulant recommended by NICE Daiichi’s new anticoagulant recommended by NICE

    Specifically, in draft guidance NICE is minded to recommend Lixiana (edoxaban) as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more ... NICE has already recommended Lixiana for the

  • Daiichi Sankyo gets EU OK for Lixiana anticoagulant Daiichi Sankyo gets EU OK for Lixiana anticoagulant

    The European Commission has given the green light for Lixiana (edoxaban) to be used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one ... or more risk factors, such as congestive heart failure

  • NICE recommends BMS and Pfizer’s Eliquis for blood clots NICE recommends BMS and Pfizer’s Eliquis for blood clots

    and pulmonary embolism (PE). ... Eliquis gained a European license for DVT and PE in July last year, having already been approved for preventing stroke and systemic embolism with non-valvular atrial fibrillation.

More from news
Approximately 4 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    embolism in patients with AF and for the prevention of VTE in patients undergoing knee or hip replacement surgery. ... In one phase III trial, idrabiotaparinux sodium was non-inferior to warfarin in preventing the recurrent VTE at three months in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics